Strong Market Performance and Price Movement
On 9 April 2026, Venus Remedies Ltd’s stock price surged to Rs.1009, marking a new 52-week and all-time high. The stock opened with a gap up of 4.07% and closed with a day gain of 5.00%, outperforming the broader Sensex, which declined by 0.43% on the same day. This price movement was accompanied by high volatility, with an intraday volatility of 925.41% calculated from the weighted average price, indicating active trading interest and dynamic price action.
The stock has been on a positive trajectory, gaining for two consecutive days and delivering a 7.99% return over this short period. It has consistently traded above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a strong bullish trend. The technical outlook remains positive, with multiple indicators such as MACD, Bollinger Bands, and Dow Theory showing bullish signals on both weekly and monthly timeframes.
Outperformance Across Multiple Time Horizons
Venus Remedies Ltd has demonstrated remarkable outperformance relative to the Sensex and its sector peers over various time frames. The stock’s returns over the last one year stand at an impressive 242.86%, vastly exceeding the Sensex’s 4.58% gain during the same period. Year-to-date, the stock has risen 32.72%, while the Sensex has declined by 9.37%. Over three years, the stock has delivered a staggering 484.69% return compared to the Sensex’s 29.08%, and over ten years, the cumulative return exceeds 1,031%, dwarfing the Sensex’s 213.01%.
Shorter-term performance also highlights the stock’s strength, with a 34.78% gain over the past month and a 40.05% increase over three months, while the Sensex recorded negative returns in these periods. This consistent outperformance underscores the company’s ability to generate shareholder value across market cycles.
Financial Strength and Quality Metrics
Venus Remedies Ltd’s financial profile supports its market performance. The company maintains a micro-cap market capitalisation and holds a strong Mojo Score of 74.0, reflecting favourable fundamentals. The Mojo Grade was upgraded from Hold to Buy on 12 March 2026, signalling improved confidence in the company’s prospects.
The company’s debt position is notably conservative, with an average debt-to-equity ratio of zero, indicating a net cash position and minimal leverage. This financial prudence is complemented by strong interest coverage, with an average EBIT to interest ratio of 37.06x, and no promoter share pledging, which enhances balance sheet stability.
Profitability metrics have shown significant improvement, with operating profit growth of 96.37% reported in the December 2025 quarter. The company has declared positive results for five consecutive quarters, with quarterly PAT reaching Rs.25.58 crores, reflecting a 116.9% increase. Return on capital employed (ROCE) reached a high of 13.99%, while inventory turnover ratio stood at 6.58 times, indicating efficient asset utilisation.
Valuation and Market Positioning
At the current price of approximately Rs.1,018, Venus Remedies Ltd trades at a price-to-earnings (P/E) ratio of 17x and a price-to-book value (P/BV) of 2.18x. The company’s PEG ratio is an exceptionally low 0.09x, reflecting strong earnings growth relative to its valuation. Enterprise value multiples such as EV/EBITDA at 9.52x and EV/EBIT at 12.04x further illustrate the company’s valuation context within the pharmaceuticals sector.
Despite trading at a premium compared to its peers’ historical valuations, the company’s robust earnings growth and improving profitability metrics justify this premium. The stock’s dividend yield is not currently available, with the latest dividend declared at Rs.3 per share, though the ex-dividend date dates back to 2013.
Institutional Participation and Market Sentiment
Institutional investors have increased their stake in Venus Remedies Ltd by 0.67% over the previous quarter, now collectively holding 3.28% of the company’s shares. This growing institutional interest reflects confidence in the company’s fundamentals and market positioning, given their greater resources and analytical capabilities.
Long-Term Growth and Quality Assessment
While the company has exhibited strong short-term financial trends and market performance, its long-term sales growth has been moderate, with a compound annual growth rate of 6.29% over the past five years. EBIT growth over the same period was more robust at 29.54%, indicating improving operational efficiency.
The company’s overall quality grade is assessed as average, with strengths in capital structure and management risk rated as average. Return on equity (ROE) and return on capital employed (ROCE) have been relatively weak on average, at 7.52% and 7.85% respectively, though recent half-year figures show improvement.
Technical Support and Trading Volumes
Technical analysis confirms a bullish trend since 12 March 2026, when the stock price crossed ₹927.5. Key support levels include the 52-week low of ₹277.85, while resistance levels at the 20-day, 100-day, and 200-day moving averages have been surpassed. Delivery volumes have surged dramatically, with a 1-month delivery change of 1987.95% and a 1-day delivery change of 10.54% compared to the 5-day average, indicating strong market participation.
Summary
Venus Remedies Ltd’s stock reaching an all-time high of Rs.1009 on 9 April 2026 marks a significant milestone in its market journey. Supported by strong financial results, conservative capital structure, and sustained outperformance against benchmarks, the company has demonstrated resilience and growth. While long-term sales growth remains moderate, recent profitability and operational metrics have improved markedly, underpinning the stock’s bullish technical trend and market valuation.
